Global Epilepsy Therapeutics Market Size study & Forecast, by Product Type (Antiepileptic Drugs (AEDs), Devices, Surgical Instruments) by End User (Hospitals, Clinics, Home care settings) and Regional Analysis, 2023-2030

Global Epilepsy Therapeutics Market Size study & Forecast, by Product Type (Antiepileptic Drugs (AEDs), Devices, Surgical Instruments) by End User (Hospitals, Clinics, Home care settings) and Regional Analysis, 2023-2030

Global Epilepsy Therapeutics Market is valued approximately USD 0.85 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 2.52%% over the forecast period 2023-2030. Epilepsy is a chronic noncommunicable disease of the brain that is characterized by recurrent, unprovoked seizures and affects people of all age group. These seizures are occurred due to the abnormal electrical activity in the brain, leading to various symptoms behavior, awareness, sensation, or consciousness depending on the affected area. This neurological condition is expected to cause by brain injury, tumor, stroke, infection, and genetic predisposition. Therapeutics such as Antiepileptic Drugs (AEDs), surgical devices, and other surgical instruments are introduced in order to cure epilepsy. The objective of epilepsy therapeutics is to control and manage seizures, improve the quality of life for individuals with epilepsy, and minimize the adverse effects of medications. The growing geriatric population, rising number of research & development activities related to epilepsy therapeutics, and rise in the new drug approvals are the key factors that anticipated to support the market growth across the globe. For instance, in March 2022, the U.S. Food and Drug Administration (FDA) granted approval for Ztalmy (ganaxolone) to address seizures linked with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged two years and above.

In addition, the rising prevalence of epilepsy worldwide have been is a significant factor driving the demand for epilepsy therapeutics. Epilepsy is a neurological condition marked by repeated and unpredictable seizures, which are abnormal, excessive electrical discharges in the brain. Growing seizures play a complex and multifaceted role in the development of epilepsy, encompassing genetic, environmental, and neurological variables. Furthermore, frequent seizures can promote the development of epilepsy. The brain's sensitivity to seizures can rise over time as a result of a phenomenon known as kindling, in which numerous or prolonged seizures reduce the threshold for future seizures. This process has the potential to start a cycle that increases the brain's susceptibility to the unprovoked, spontaneous seizures that are a characteristic of epilepsy. According to the World Health Organisation, epilepsy affects around 50 million people globally, making it one of the most common neurological diseases. Nearly 80% of epilepsy patients live in low- and middle-income countries. In addition, according to the World Health Organisation, epilepsy affects around 50 million people globally, making it one of the most common neurological diseases. Nearly 80% of epilepsy patients live in low- and middle-income countries. Moreover, technological advancements associated to epilepsy-based therapeutics devices, as well as government awareness campaigns regrading epilepsy are anticipated to create the lucrative opportunities for the market growth over forecast period of 2023-2030. However, the side effects associated to anti-epilepsy medications and high treatment cost associated to epilepsy are likely to stifles the market growth during the estimated years.

The key regions considered for the Global Epilepsy Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising incidence and prevalence of epilepsy, supportive government initiatives and funding for research and development, presence of key market players, and growing healthcare spending. Whereas, the Asia Pacific is expected to grow with the fastest growth of 5.13% rate during the forecast period, owing to factors such as the increasing geriatric population, supportive government initiatives to improve the healthcare infrastructure, growing related research and development activities, and rising prevalence of epilepsy.

Major market player included in this report are:
Pfizer, Inc.
UCB S.A.
Bausch Health Companies Inc.
Novartis AG
GlaxoSmithKline plc.
Boston Scientific Corporation
Sumitomo Pharma Co., Ltd.
Eisai Co. Ltd
Upsher-Smith Laboratories, LLC
Aleva Neurotherapeutics

Recent Developments in the Market:
In December 2022, UCB announced a collaboration with Praxis Precision Medicines, Inc. centered around Praxis' PRAX-020 program, aimed at discovering small molecule therapeutics for potential treatments of KCNT1-related epilepsies. As part of the agreement, UCB retains the exclusive option to in-license global development and commercialization rights for any emerging KCNT1 small molecule development candidate. Praxis is set to receive an upfront payment from UCB. Additionally, Praxis stands to receive tiered royalties based on net sales of any resulting products arising from the collaboration.
In July 2023, Novartis has announced its acquisition of DTx Pharma, a preclinical stage biotechnology company based in San Diego. DTx Pharma is focused on harnessing its proprietary FALCON platform to develop siRNA therapies targeting neuroscience indications. This strategic move not only includes DTx-1252 but also introduces two additional preclinical programs addressing different neuroscience indications to Novartis. The acquisition further expands Novartis' siRNA toolkit, complementing its capabilities in xRNA, a key technology platform. This agreement reflects Novartis' strong commitment to Neuroscience, a core therapeutic area for the company, emphasizing its dedication to advancing innovative therapies for patients dealing with neuromuscular disorders.
In March 2022, the U.S. Food and Drug Administration approved Marinus Pharmaceuticals' medication, Ztalmy, for addressing seizures in individuals diagnosed with CDKL5 deficiency, a hereditary form of epilepsy.
In March 2022, The United States Food and Drug Administration granted approval to Lupin for its Abbreviated New Drug Application (ANDA) concerning Vigabatrin. This anti-epileptic drug is authorized in the form of an oral solution USP (500 mg).
Global Epilepsy Therapeutics Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Product Type, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product Type:
Antiepileptic Drugs (AEDs)
Devices
Surgical Instruments

By End User:
Hospitals
Clinics
Home care settings

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa